Business Context and Reporting Period
The Clorox Company’s Form 10-K covers the fiscal year ended June 30, 2022, not calendar-year 2021 or a standalone fourth quarter. Clorox is a multinational consumer and professional products company with fiscal 2022 net sales of $7.1 billion and approximately 9,000 employees. Its four reportable segments are Health and Wellness, Household, Lifestyle and International. The filing’s detailed MD&A and financial statements are incorporated by reference in Exhibit 99.1, which is not included in the supplied text.
Financial Performance and Key Metrics
- Sales and earnings: Net sales decreased 3% and diluted EPS decreased 33% versus fiscal 2021, when COVID-related demand for essential household products, particularly cleaning and disinfecting products, was elevated.
- Margins and costs: Management said significant inflationary pressures affected gross margin in fiscal 2022. Raw material, commodity, manufacturing, labor, transportation and logistics costs were elevated.
- Cash flow and liquidity: The supplied filing text does not provide clear values for operating cash flow, free cash flow, cash balances, or current liquidity measures.
- Debt: Clorox reported nearly $3 billion of debt as of June 30, 2022. The supplied text does not provide a detailed debt maturity schedule or leverage ratio. Its credit ratings remained investment grade at fiscal year-end.
- Dividends and repurchases: Clorox paid $571 million in dividends during fiscal 2022. In July 2022, it announced a 2% increase in its quarterly dividend. No shares were purchased under the publicly announced open-market program during the fourth quarter; $993 million remained authorized.
- Sales concentration: Cleaning products accounted for 42% of sales, bags and wraps 16%, and food products 11%. The United States represented 84% of net sales and international markets 16%. Walmart and affiliates accounted for 25% of consolidated sales; the five largest customers represented nearly half.
Material Changes Versus the Prior Comparable Period
- Sales and diluted EPS declined year over year, against a prior-year comparison period with unusually strong pandemic-related demand for cleaning and disinfecting products.
- Inflation and persistent supply-chain pressures weighed on gross margin and increased uncertainty. The filing also cites the war in Ukraine as an added source of cost, logistics and foreign-exchange volatility.
- International sales grew, supported by demand for cleaning and disinfecting products and household essentials; the supplied text does not quantify the growth rate.
Outlook, Management Commentary, Risks and Unusual Items
- Fiscal 2023 outlook: Management anticipated continued uncertainty from the pandemic, high manufacturing, logistics and commodity costs, the Ukraine conflict, changing consumer behavior, competition, foreign exchange and macroeconomic conditions. The supplied text does not provide quantified fiscal 2023 sales, earnings or margin guidance.
- Restructuring: A streamlined operating model announced in August 2022 was expected to generate approximately $75 million to $100 million in restructuring, implementation and other costs across fiscal 2023 and 2024, including about $35 million in fiscal 2023.
- Digital investment: Clorox planned to invest approximately $500 million over five years beginning in fiscal 2022 in digital capabilities and productivity, including replacing its enterprise resource planning system and moving to a cloud-based platform.
- Glad venture obligation: Clorox’s agreement with Procter & Gamble requires it to purchase P&G’s 20% interest in the Glad business when the agreement expires in January 2026, unless extended. The interest was estimated at $635 million as of June 30, 2022; $468 million was recognized as a liability. The eventual amount and related earnings impact depend on valuation assumptions.
- Other risks and contingencies: The filing highlights commodity and transport inflation, supply disruptions and single-source suppliers, customer concentration, competition and pricing risks, labor pressures, cyber and technology risks, international and foreign-exchange exposure, regulatory and ESG risks, and product liability and litigation exposure. A recorded environmental remediation liability was $28 million at June 30, 2022, unchanged from 2021; actual exposure could exceed the recorded amount.
- Litigation: Clorox described routine litigation and stated that, based on management’s analysis, matters not otherwise provided for or disclosed were not expected to have a material adverse effect individually or in aggregate. Outcomes remain uncertain.
Important Facts for Investors to Verify
- Review Exhibit 99.1 for the complete audited financial statements and MD&A, including exact revenue, net income, margins, cash flows, cash and liquidity, debt details, and segment results.
- Check the fiscal 2023 guidance and subsequent disclosures against the cost-inflation, supply-chain and demand risks described in this filing.
- Track the timing, cash costs and expected benefits of the $500 million digital investment and the $75 million to $100 million restructuring program.
- Monitor the valuation and accounting of the Glad purchase obligation ahead of the January 2026 agreement expiration.
- Assess the implications of Walmart’s 25% sales share and the five largest customers’ nearly half of sales, along with Clorox’s ability to pass through higher costs without losing volume or share.
- Review developments in environmental remediation, litigation, debt maturities and the company’s ability to sustain dividends amid elevated costs and debt.